tiprankstipranks
Trending News
More News >
Rapt Therapeutics Inc (RAPT)
:RAPT
US Market

RAPT Therapeutics (RAPT) Stock Forecast & Price Target

Compare
442 Followers
See the Price Targets and Ratings of:

RAPT Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
RAPT
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RAPT Stock 12 Month Forecast

There Are No Analyst Ratings for RAPT In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

RAPT Financial Forecast

RAPT Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.

RAPT Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on RAPT
Leerink Partners
Leerink Partners
$58
Hold
-0.03%
Downside
Downgraded
01/21/26
Rapt Therapeutics downgraded to Market Perform from Outperform at LeerinkRapt Therapeutics downgraded to Market Perform from Outperform at Leerink
Barclays Analyst forecast on RAPT
Barclays
Barclays
$56$58
Hold
-0.03%
Downside
Downgraded
01/21/26
Rapt Therapeutics downgraded to Equal Weight from Overweight at BarclaysRapt Therapeutics downgraded to Equal Weight from Overweight at Barclays
Wells Fargo Analyst forecast on RAPT
Wells Fargo
Wells Fargo
$72$58
Hold
-0.03%
Downside
Downgraded
01/21/26
Rapt Therapeutics downgraded to Equal Weight from Overweight at Wells FargoRapt Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
LifeSci Capital Analyst forecast on RAPT
LifeSci Capital
LifeSci Capital
$68$58
Hold
-0.03%
Downside
Downgraded
01/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Corvus Pharmaceuticals (NASDAQ: CRVS) and RAPT Therapeutics (NASDAQ: RAPT)
TD Cowen Analyst forecast on RAPT
TD Cowen
TD Cowen
Hold
Downgraded
01/20/26
Rapt Therapeutics downgraded to Hold from Buy at TD CowenRapt Therapeutics downgraded to Hold from Buy at TD Cowen
Guggenheim Analyst forecast on RAPT
Guggenheim
Guggenheim
Hold
Downgraded
01/20/26
Rapt Therapeutics downgraded to Neutral from Buy at GuggenheimRapt Therapeutics downgraded to Neutral from Buy at Guggenheim
Piper Sandler Analyst forecast on RAPT
Piper Sandler
Piper Sandler
$95$58
Hold
-0.03%
Downside
Downgraded
01/20/26
Rapt Therapeutics downgraded to Neutral from Overweight at Piper SandlerRapt Therapeutics downgraded to Neutral from Overweight at Piper Sandler
H.C. Wainwright Analyst forecast on RAPT
H.C. Wainwright
H.C. Wainwright
$72$58
Hold
-0.03%
Downside
Downgraded
01/20/26
Rapt Therapeutics downgraded to Neutral from Buy at H.C. WainwrightRapt Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Clear Street Analyst forecast on RAPT
Clear Street
Clear Street
$60$58
Hold
-0.03%
Downside
Downgraded
01/20/26
Rapt Therapeutics downgraded to Hold from Buy at Clear StreetRapt Therapeutics downgraded to Hold from Buy at Clear Street
J.P. Morgan Analyst forecast on RAPT
J.P. Morgan
J.P. Morgan
$55$57
Buy
-1.76%
Downside
Reiterated
11/11/25
J.P. Morgan Remains a Buy on RAPT Therapeutics (RAPT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on RAPT
Leerink Partners
Leerink Partners
$58
Hold
-0.03%
Downside
Downgraded
01/21/26
Rapt Therapeutics downgraded to Market Perform from Outperform at LeerinkRapt Therapeutics downgraded to Market Perform from Outperform at Leerink
Barclays Analyst forecast on RAPT
Barclays
Barclays
$56$58
Hold
-0.03%
Downside
Downgraded
01/21/26
Rapt Therapeutics downgraded to Equal Weight from Overweight at BarclaysRapt Therapeutics downgraded to Equal Weight from Overweight at Barclays
Wells Fargo Analyst forecast on RAPT
Wells Fargo
Wells Fargo
$72$58
Hold
-0.03%
Downside
Downgraded
01/21/26
Rapt Therapeutics downgraded to Equal Weight from Overweight at Wells FargoRapt Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
LifeSci Capital Analyst forecast on RAPT
LifeSci Capital
LifeSci Capital
$68$58
Hold
-0.03%
Downside
Downgraded
01/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Corvus Pharmaceuticals (NASDAQ: CRVS) and RAPT Therapeutics (NASDAQ: RAPT)
TD Cowen Analyst forecast on RAPT
TD Cowen
TD Cowen
Hold
Downgraded
01/20/26
Rapt Therapeutics downgraded to Hold from Buy at TD CowenRapt Therapeutics downgraded to Hold from Buy at TD Cowen
Guggenheim Analyst forecast on RAPT
Guggenheim
Guggenheim
Hold
Downgraded
01/20/26
Rapt Therapeutics downgraded to Neutral from Buy at GuggenheimRapt Therapeutics downgraded to Neutral from Buy at Guggenheim
Piper Sandler Analyst forecast on RAPT
Piper Sandler
Piper Sandler
$95$58
Hold
-0.03%
Downside
Downgraded
01/20/26
Rapt Therapeutics downgraded to Neutral from Overweight at Piper SandlerRapt Therapeutics downgraded to Neutral from Overweight at Piper Sandler
H.C. Wainwright Analyst forecast on RAPT
H.C. Wainwright
H.C. Wainwright
$72$58
Hold
-0.03%
Downside
Downgraded
01/20/26
Rapt Therapeutics downgraded to Neutral from Buy at H.C. WainwrightRapt Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Clear Street Analyst forecast on RAPT
Clear Street
Clear Street
$60$58
Hold
-0.03%
Downside
Downgraded
01/20/26
Rapt Therapeutics downgraded to Hold from Buy at Clear StreetRapt Therapeutics downgraded to Hold from Buy at Clear Street
J.P. Morgan Analyst forecast on RAPT
J.P. Morgan
J.P. Morgan
$55$57
Buy
-1.76%
Downside
Reiterated
11/11/25
J.P. Morgan Remains a Buy on RAPT Therapeutics (RAPT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering RAPT Therapeutics

3 Months
xxx
Success Rate
7/10 ratings generated profit
70%
Average Return
+34.29%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +34.29% per trade.
1 Year
Anupam RamaJ.P. Morgan
Success Rate
5/10 ratings generated profit
50%
Average Return
-1.89%
reiterated a buy rating 4 months ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -1.89% per trade.
2 Years
xxx
Success Rate
3/10 ratings generated profit
30%
Average Return
-23.03%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 30.00% of your transactions generating a profit, with an average return of -23.03% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RAPT Analyst Recommendation Trends

Rating
Sep 25
Oct 25
Nov 25
Dec 25
Jan 26
Strong Buy
8
14
16
15
10
Buy
1
4
4
4
5
Hold
2
2
0
1
24
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
20
20
20
39
In the current month, RAPT has received 15 Buy Ratings, 24 Hold Ratings, and 0 Sell Ratings. RAPT average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

RAPT Stock Forecast FAQ

What is RAPT’s average 12-month price target, according to analysts?
Currently, no data Available
What is RAPT’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for RAPT, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is RAPT a Buy, Sell or Hold?
      Currently, no data Available
      What is Rapt Therapeutics Inc’s price target?
      Currently, no data Available
      What do analysts say about Rapt Therapeutics Inc?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of RAPT?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.